Alcon, Inc. (ALC)

NYSE: ALC · IEX Real-Time Price · USD
58.18
+0.23 (0.40%)
Sep 30, 2022 4:00 PM EDT - Market closed
0.40%
Market Cap 29.22B
Revenue (ttm) 8.66B
Net Income (ttm) 457.00M
Shares Out 502.23M
EPS (ttm) 0.92
PE Ratio 63.24
Forward PE 22.88
Dividend $0.20 (0.35%)
Ex-Dividend Date May 3, 2022
Volume 1,351,418
Open 58.33
Previous Close 57.95
Day's Range 56.96 - 59.23
52-Week Range 56.18 - 88.78
Beta 0.71
Analysts Buy
Price Target 83.19 (+43.0%)
Earnings Date Aug 16, 2022

About ALC

Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surg... [Read more...]

Industry Medical Instruments & Supplies
Founded 1945
CEO David Endicott
Employees 24,000
Stock Exchange NYSE
Ticker Symbol ALC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for ALC stock is "Buy." The 12-month stock price forecast is 83.19, which is an increase of 42.99% from the latest price.

Price Target
$83.19
(42.99% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

3 days ago - Business Wire

AERIE PHARMACEUTICALS - INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigat...

NEW ORLEANS , Sept. 27, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

5 days ago - PRNewsWire

Alcon (ALC) Faces Cost Pressure, Supply Chain Disruption

Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.

2 weeks ago - Zacks Investment Research

AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigat...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Aerie Pharmaceutic...

Other symbols: AERI
1 month ago - Business Wire

Don't Look for Alcon's Acquisition to Boost Share Price in Short Term

Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.

Other symbols: AERINVS
1 month ago - GuruFocus

Aerie set to be bought by Alcon for $770 million

New Jersey-based biotech firm Aerie is seeing its shares move higher amid news of it being bought by Aerie Pharmaceuticals.

1 month ago - Yahoo Finance

SHAREHOLDER ALERT: Weiss Law Investigates Aerie Pharmaceuticals, Inc.

NEW YORK , Aug. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" or t...

Other symbols: AERI
1 month ago - PRNewsWire

Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million

Alcon will buy glaucoma drugs maker Aerie Pharmaceuticals in a $770 million deal that sent the biotech stock flying Tuesday. The post Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie ...

1 month ago - Investors Business Daily

Alcon to Acquire Aerie Pharmaceuticals for $15.25 a Share

Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.

Other symbols: AERI
1 month ago - Barrons

Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

GENEVA & DURHAM, N.C.--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, ...

Other symbols: AERI
1 month ago - Business Wire

Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.

1 month ago - Zacks Investment Research

Alcon Reports Second Quarter 2022 Results

GENEVA--(BUSINESS WIRE)--Alcon Reports Second Quarter 2022 Results

1 month ago - Business Wire

Here's Why Alcon (ALC) is a Great Momentum Stock to Buy

Does Alcon (ALC) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 months ago - Zacks Investment Research

Alcon's (ALC) Product Launches, Market Recovery Aid Growth

Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.

2 months ago - Zacks Investment Research

Here's Why Alcon (ALC) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

2 months ago - Zacks Investment Research

Algoma Central Corporation Announces Sale of Station Mall in Sault Ste. Marie

ST. CATHARINES, Ontario--(BUSINESS WIRE)---- $ALC--Algoma Central Corporation (TSX: ALC) announced today that it has sold Station Mall, a large regional shopping complex located in Sault Ste. Marie, Ont...

2 months ago - Business Wire

Here's Why Investors Should Retain Alcon (ALC) Stock For Now

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.

3 months ago - Zacks Investment Research

Alcon Prices EUR 500.0 Million Senior Notes Offering

GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500.0 Million Senior Notes Offering

4 months ago - Business Wire

Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals

The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.

4 months ago - Zacks Investment Research

Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio

GENEVA--(BUSINESS WIRE)--Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio

4 months ago - Business Wire

Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow

Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.

4 months ago - Zacks Investment Research

Alcon Reports First Quarter 2022 Results

GENEVA--(BUSINESS WIRE)--Alcon Reports First Quarter 2022 Results

4 months ago - Business Wire

3 Medical Product Stocks Set to Beat on Earnings This Season

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.

Other symbols: ABTCGCHAEISRG
4 months ago - Zacks Investment Research

Alcon Announces Results of 2022 Annual General Meeting

GENEVA--(BUSINESS WIRE)--Alcon Announces Results of 2022 Annual General Meeting

5 months ago - Business Wire

3 Medical Product Stocks Poised to Beat This Earnings Season

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.

Other symbols: ABTCSIIISRGZBH
5 months ago - Zacks Investment Research